Project Grant R01AI195539
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $676,666 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2025, to develop an advanced influenza messenger ribonucleic acid (mRNA) vaccine delivery system. The research aims to address critical limitations of current mRNA vaccines, including cold-chain storage requirements, reduced immunogenicity, and waning immunity. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $453,750 on June 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an innovative high-throughput airway organoid screening platform. This research project, scheduled for completion by May 31, 2027, focuses on identifying novel mechanisms of communication between airway epithelial cells (AECs) and intraepithelial...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $197,640 to Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, for a five-year project period concluding June 30, 2030. This Project Grant funds investigator-initiated research to advance understanding of sepsis immunopathogenesis through single-cell ribonucleic acid sequencing (scRNA-seq) and functional immunological...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital a Project Grant of $439,088 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 8, 2025, through July 7, 2027. The award supports research led by Dr. Daniel Lingwood, Associate Professor of Medicine at the Ragon Institute of Mass General, MIT and Harvard, to mechanistically define how sex differences in hormones and...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Massachusetts General Hospital (MGH) for the period August 1, 2025 through July 31, 2027. This research project investigates the cellular and molecular mechanisms of neutrophil swarming in response to Pseudomonas aeruginosa microcolony aggregates. The research deliverables include...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 24, 2025, with a completion date of June 30, 2027. The award funds structural research aimed at determining the high-resolution three-dimensional structure of the full-length nucleocapsid (N) protein of Severe Acute Respiratory Syndrome Coronavirus 2...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $436,454 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, for a two-year project concluding January 31, 2028. This Project Grant supports investigator-initiated biomedical research examining the gastrointestinal tract's role in systemic alloimmunity following allogeneic hematopoietic cell transplantation. The research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital) on July 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Overcoming Obstacles in Structural Elucidation of B Cell Antigen Receptor Assembly and Lateral Interaction," will be conducted through June 30, 2027, in Massachusetts. The research...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $800,557 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 19, 2026, with a completion date of January 31, 2031. This project grant supports biomedical research investigating how the gram-positive pathogen Staphylococcus aureus manipulates inflammasome activities critical to host immune defense. The research focuses...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $445,000 to Boston Children's Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 18, 2026, with a completion date of January 31, 2031. This project grant funds investigator-initiated biomedical research examining novel immunoregulatory mechanisms that modulate myeloid trained immunity in organ transplant recipients. The research addresses a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $661,313 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, for a research project titled "Elicitation of Pan-Influenza A Antibodies via Simple B Cell Development Pathways." Led by Principal Investigator Dr. Daniel Lingwood with Co-Investigators Dr. Batista and Dr. Andrew Ward, this R01 project will deliver research and development services focused on universal influenza vaccine development through February 2031. The research team will design and test engineered nanoparticle immunogens intended to elicit cross-group influenza A virus (IAV) immunity by selectively triggering germline B cell receptors encoding broadly neutralizing antibodies that can accommodate glycosylation diversity on the hemagglutinin stem, potentially protecting against all IAV strains and pandemic variants. The project will generate scientific products including immunological characterization studies using humanized mouse vaccine models, structural analysis of antibody-antigen complexes via cryo-electron microscopy, and experimental validation of vaccine-elicited antibody responses with cross-group protection capabilities. Research outputs are expected to inform rational vaccine design strategies and advance understanding of B cell immunological decision-making mechanisms relevant to infectious disease prevention. The work will be performed at the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard in Boston, Massachusetts, with structural biology support from Scripps Institution.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $661.3k | 2/6/26 |